Share buyback sets the stage for renewed focus on Novo Nordisk Novo Nordisk (NVO) triggered fresh attention after launching a DKK 15b share repurchase programme, committing up to DKK 11.2b to B shares through early 2027 and already retiring tens of millions of shares. For investors watching Novo Nordisk, the backdrop to this buyback is a share price that has slipped to US$38.06, with the 30-day share price return down 11.63% and the year-to-date share price return down 27.35%. The 1-year total shareholder return has declined 30.54%, pointing to fading momentum even as Wegovy pill approval, higher 2026 guidance, and intensifying GLP-1 competition all reshape how the market prices both its growth potential and risk profile.
Mostramos publicamente o ponto principal. Crie uma conta gratuita para continuar lendo o artigo completo, salva-lo, comenta-lo e conecta-lo ao contexto de mercado e OSINT.